BioVersys AGFRA:W33 -0.71%7 Pretax Margin % is -1,350.99% as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 7/100. Among 938 Biotechnology companies, BioVersys AG ranks worse than 85.82% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. BioVersys AG's Pre-Tax Income for the
six
months ended in Dec. 2025 was €-11.58 Mil. BioVersys AG's Revenue for the
six
months ended in Dec. 2025 was €0.86 Mil. Therefore, BioVersys AG's pretax margin for the quarter that ended in Dec. 2025 was -1,350.99%.
The historical rank and industry rank for BioVersys AG's Pretax Margin % or its related term are showing as below:
FRA:W33'
s Pretax Margin % Range Over the Past 10 Years
Min: -2726.75 Med: -2726.75 Max: -2726.75
Current: -2726.75
FRA:W33's Pretax Margin % is ranked worse than 85.82% of 938
companies
in the Biotechnology industry
Industry Median: -89.895
vs FRA:W33: -2726.75
BioVersys AG (FRA:W33) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
BioVersys AG Pretax Margin % Related Terms
BioVersys AG Pretax Margin % Historical Data
* Premium members only.
The historical data trend for BioVersys AG's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG Pretax Margin % Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
Pretax Margin %
0.00
-2,727.77
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
Pretax Margin %
0.00
0.00
0.00
-1,350.99
FRA:W33 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, BioVersys AG's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where BioVersys AG's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (FRA:W33) has a Pretax Margin % of -1,350.99% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioVersys AG and its competitors. According to the industry distribution chart, BioVersys AG ranks #805 out of 938 companies in the Biotechnology industry, placing it in the top 85.8%.
Is BioVersys AG's Pretax Margin % too high?
BioVersys AG's current Pretax Margin % is -1,350.99%. Based on the distribution chart, BioVersys AG ranks #805 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #805 out of 938 companies for Pretax Margin %. This places BioVersys AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioVersys AG and its competitors. BioVersys AG's current Pretax Margin % is -1,350.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current Pretax Margin % of -1,350.99%. The current Pretax Margin % is -1,350.99%. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current Pretax Margin % is -1,350.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score
Get the complete analysis for FRA:W33
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:W33 has been successfully added to your 